Withdraw BRAI bill: Greenpeace to Centre

Image
Press Trust of India New Delhi
Last Updated : Apr 24 2013 | 6:35 PM IST
An environmental NGO today asked the government to withdraw the controversial Biotechnology Regulatory Authority of India (BRAI) bill, which aims at introducing genetically modified food crops in the country, and bring in a law to protect and enhance bio-safety.
"In light of the controversy around the bill and its potential to impact all of us and future generations, we urge you, as the minister in charge, to withdraw the BRAI bill and work with other relevant ministries to bring in a bio-safety law," NGO Greenpeace said in a letter to Science and Technology Minister Jaipal Reddy.
The BRAI bill, which seeks to establish a statutory independent regulator for biotech sector covering research, transport, import, manufacture and use of organisms and products of modern biotechnology, was introduced in the Lok Sabha on Monday.
The bill, which has been on the drafting board for years and had run into stiff opposition from green activists, was introduced by Reddy.
In its letter, Greenpeace alleged the bill was drafted in a "secretive fashion with no opportunity for the general public to comment" on a legislation that deals with something as important as food safety.
"It is unfortunate that this is happening despite the strong recommendation from a Parliamentary standing committee on Agriculture against such a regulation with a limited mandate," it said.
Introducing the bill, Reddy had said it was being done within the legislative competence of Parliament.
According to the bill, the proposed regulator would be a nodal agency of the government to ensure comprehensive safety assessment of organisms and products of modern biotechnology. The commercialisation of biotechnology products in agriculture and healthcare would be subject to all other laws for the time being in force.
As per the bill, the biotech regulator would regulate trials preceding the clinical trials in the health sector and the present mechanism for regulating clinical trials would continue.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 24 2013 | 6:35 PM IST

Next Story